14 Ministries Crack Down Hard on Medical Aesthetics Irregularities: A Golden Window for Compliant OEM Manufacturers

The self-inspection and rectification transition period has ended, and the industry has entered a stage of zero-tolerance strict scrutiny.

Starting July 1, 2026, the self-inspection and rectification transition period for the national medical aesthetics industry officially ended, and the industry has fully entered a new stage of "zero buffer, zero tolerance" strict scrutiny. The "2026 Work Priorities for Correcting Unhealthy Practices in the Field of Pharmaceutical Procurement and Medical Services," jointly issued by 14 ministries and commissions including the National Health Commission, the Ministry of Public Security, and the State Administration for Market Regulation, has brought the intensity of rectification in the medical aesthetics industry to an unprecedented level.

This is not merely a simple upgrade in regulation, but a key signal of industry reshuffling. For contract manufacturers and production enterprises that adhere to compliance bottom lines, this precisely means new opportunities are arriving.

What exactly is being inspected this time? Full coverage of six links

Unlike previous special rectification campaigns, this inspection covers six core links including institutions and personnel, drugs and devices, technology, advertising, and services, forming closed-loop supervision across the entire chain.

In terms of institutional and personnel qualifications, the focus is on verifying the validity period of practice licenses, whether diagnosis and treatment subjects exceed the scope, and whether medical staff practice certificates are registered with the institution. Separation of person and certificate, and non-medical-aesthetics professional doctors performing plastic surgery injection projects, have long been chronic problems in the industry and are explicitly listed this time as key targets for crackdown.

In terms of drug and device traceability, the procurement channels, purchase vouchers, and traceability ledgers of injectable consumables such as botulinum toxin and hyaluronic acid must be checked one by one. Smuggled goods, counterfeit goods, and unlabeled products that are repackaged and blended face severe crackdown. Photoelectric equipment such as facial radiofrequency instruments must hold Class III medical device registration certificates; those without them must be suspended from use.

In terms of advertising and promotion, short video platforms, Xiaohongshu seeding, store posters, and online group buying are all included in the inspection scope. Without medical advertising review qualifications, no promotional content may be published, and marketing methods such as before-and-after comparisons, exaggerated effects, creating appearance anxiety, and using patient cases as endorsements are strictly prohibited.

It is worth noting that the 14 departments have listed three major issues as key rectification targets: "providing medical aesthetics services without qualifications," "illegally conducting lightweight medical aesthetics crash courses," and "false commercial marketing." This means that from upstream products to terminal services, the entire industry chain is within the regulatory vision.

Five types of violations lead to direct expulsion, with higher fines of 500,000 yuan

After July 1, five types of violating institutions and individuals will be directly expelled from the market: those engaged in injection, photoelectric, or surgical medical aesthetics projects without qualifications will not only be expelled from the industry but also face fines of 30,000 to 100,000 yuan, and in serious cases, be banned from practicing for life. Those whose certificates have expired and have not been verified in a timely manner will be treated as practicing medicine without a license. For certificate affiliation and separation of person and certificate, both the physician and the institution involved will be punished, and in serious cases, the business license will be directly revoked. Non-medical-aesthetics professional doctors practicing beyond their scope or illegal operation of black medical aesthetics studios will face higher fines of 500,000 yuan and store closure. If illegal operations lead to medical accidents, criminal liability will also be pursued.

This level of punishment is the first of its kind in the history of medical aesthetics regulation, and the signal it sends is very clear: compliance is not a multiple-choice question, but a mandatory question for survival.

What does this mean for contract manufacturers and production enterprises?

Tighter industry regulation may appear on the surface to be a constraint, but in essence it is reshaping the market competition landscape. As non-compliant institutions and products are accelerated out of the market, the market space for compliant enterprises is actually expanding.

From the product side, the entry threshold for medical device products has further increased. In June 2026, the National Medical Products Administration intensively issued multiple regulations: dynamic adjustment of the classification catalog has become normalized, popular categories such as radiofrequency therapeutic instruments have been included in Class III management, the new version of GMP inspection standards is open for comments, and full-chain UDI traceability has become a mandatory requirement. These changes place higher demands on production enterprises' quality management systems and registration application capabilities.

From the demand side, when medical aesthetics institutions choose contract manufacturing partners, qualification compliance, complete licenses and certificates, and traceable quality will become leading considerations. Suppliers that survive on low prices and edge-ball tactics are being eliminated, while leading contract manufacturers with more than 100 Class II medical device registration certificates, ISO13485 certification, and complete quality management systems are ushering in a trend of order concentration.

According to industry data, in the first half of 2026, the lightweight medical aesthetics market continued to maintain double-digit growth, and non-surgical medical aesthetics services accounted for 47.4%. Consumers are shifting from "short-term results" to "long-term anti-aging," and from "exaggerated transformation" to "natural fine-tuning," with increasingly higher requirements for product safety and effectiveness. This shift in consumption logic is both a challenge and a benefit for upstream production enterprises.

Compliance capability building is long-term competitiveness

Facing the trend of normalized regulation, production enterprises need to continue investing in the following aspects:

Quality system upgrade. The draft of the new version of GMP for comments has greatly refined defect determination standards, and full-process UDI traceability, sterilization process validation, commissioned production management, and shared-line clearance have been listed as core inspection items. Enterprises need to complete system upgrades in accordance with the new standards, rather than waiting until an unannounced inspection arrives to make passive rectifications.

Registration certificate reserves. The transition period for classification adjustments is coming to an end, and existing products need to complete category switching as soon as possible. At the same time, new product research and development must fully consider the requirements of the new classification catalog to avoid rejection during application due to classification errors.

Compliant promotion system. The "first year of compliance" for online marketing has arrived. The live-streaming e-commerce management measures are deeply linked with the Advertising Law, and influencer sales of medical aesthetics products have been explicitly prohibited. Production enterprises' own product promotion, investment materials, and official website content all require comprehensive compliance review.

Traceability capability building. From raw material procurement to finished product shipment, full-chain traceability is not only a regulatory requirement but also a core competitiveness for winning the trust of brand customers.

The industry turning point has arrived

The medical aesthetics industry in 2026 is undergoing a key transition from wild growth to standardized development. The joint rectification by 14 ministries and commissions is not the end, but a milestone in the industry's compliance process.

For leading contract manufacturing enterprises like Weitai Group, which has been engaged in medical aesthetics functional skincare for 25 years, owns four smart factories, and has more than 100 Class II medical device certificates, tighter regulation is not a threat but a moat. When the tide goes out, truly capable enterprises will surface.

The next decade of the industry belongs to those enterprises that engrave compliance into their bones and pursue quality to the extreme.